RCEL - AVITA Medical Inc
IEX Last Trade
9.37
0.260 2.775%
Share volume: 100,098
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$9.11
0.26
2.85%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-11 | 2022-11-10 | 2023-02-23 | 2023-05-11 | 2023-08-10 | 2023-11-09 | 2024-02-22 | 2024-05-13 | |
Assets | |||||||||
Total Assets | 102.669 M | 99.932 M | 98.264 M | 92.622 M | 86.330 M | 81.014 M | 111.640 M | 97.381 M | |
Current Assets | 91.806 M | 91.720 M | 87.458 M | 82.761 M | 77.495 M | 73.927 M | 104.006 M | 85.986 M | |
Inventories | 2.022 M | 1.960 M | 2.125 M | 2.811 M | 3.058 M | 4.377 M | 5.596 M | 7.171 M | |
Other Current Assets | 1.005 M | 1.041 M | 1.578 M | 1.481 M | 2.194 M | 3.356 M | 1.659 M | 3.523 M | |
Short Term Investments | 1.005 M | 1.041 M | 1.578 M | 1.481 M | 2.194 M | 3.356 M | 1.659 M | 3.523 M | |
Total Receivables | 4.222 M | 4.345 M | 4.413 M | 5.018 M | 6.196 M | 6.076 M | 7.694 M | 7.109 M | |
Current Cash | 84.355 M | 84.172 M | 79.342 M | 73.451 M | 66.047 M | 60.118 M | 89.057 M | 68.183 M | |
Total Non-current Assets | 10.863 M | 8.212 M | 10.806 M | 9.861 M | 8.835 M | 7.087 M | 7.634 M | 11.395 M | |
Property Plant Equipment | 1.249 M | 1.226 M | 1.200 M | 1.333 M | 1.598 M | 1.862 M | 1.877 M | 4.297 M | |
Other Assets | 2.443 M | 1.577 M | 973.000 K | 2.045 M | 1.936 M | 2.843 M | 2.795 M | 3.676 M | |
Intangible Assets | 428.000 K | 449.000 K | 465.000 K | 461.000 K | 456.000 K | 459.000 K | 487.000 K | 542.000 K | |
Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 102.669 M | 99.932 M | 98.264 M | 92.622 M | 86.330 M | 81.014 M | 111.640 M | 97.381 M | |
Total liabilities | 10.109 M | 11.946 M | 13.524 M | 15.061 M | 17.683 M | 18.036 M | 61.891 M | 64.812 M | |
Total current liabilities | 7.886 M | 9.513 M | 10.693 M | 11.486 M | 13.810 M | 11.836 M | 13.199 M | 11.862 M | |
Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Other liabilities | 1.528 M | 740.000 K | 698.000 K | 382.000 K | 374.000 K | 365.000 K | 3.515 M | 5.204 M | |
Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Long term debt | 532.000 K | 405.000 K | 306.000 K | 1.235 M | 1.047 M | 1.845 M | 41.514 M | 43.833 M | |
Other liabilities | 1.528 M | 740.000 K | 698.000 K | 382.000 K | 374.000 K | 365.000 K | 3.515 M | 5.204 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 92.560 M | 87.986 M | 84.740 M | 77.561 M | 68.647 M | 62.978 M | 49.749 M | 32.569 M | |
Common stock | 24.971 M | 25.007 M | 25.084 M | 25.202 M | 25.240 M | 25.402 M | 25.481 M | 25.638 M | |
Retained earnings | -251.647 M | -257.235 M | -262.588 M | -271.808 M | -282.192 M | -290.904 M | -297.969 M | -316.627 M |